Metersky Mark, Chalmers James
Division of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut School of Medicine, Farmington, USA.
Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Dundee, UK.
F1000Res. 2019 Mar 15;8. doi: 10.12688/f1000research.17295.1. eCollection 2019.
Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.
支气管扩张症是一种日益常见的疾病，对受影响患者的生活质量和发病率有重大影响。它也是一种非常异质性的疾病，有许多不同的潜在病因和表现形式。大多数支气管扩张症的治疗基于低质量的证据；因此，美国食品药品监督管理局或欧洲药品管理局尚未批准任何治疗支气管扩张症的药物。在过去几年中，进行了大量临床试验，其中被认为具有巨大潜力的研究药物并未显示出临床或统计学上的显著益处。本评论将回顾这些令人失望结果的可能原因，以及一种可能更有可能确定支气管扩张症循证治疗方法的潜在途径。
